Randox Adiponectin is an automated biochemistry reagent, used as a biomarker which can powerfully predict the development of pathologies such as Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD).
Adiponectin is a protein hormone with anti-inflammatory and insulin-sensitizing properties. It plays an important role in a number of metabolic processes such as glucose regulation and fatty acid oxidation.
Adiponectin levels are inversely correlated with abdominal visceral fat (AVF), which has proven to be a strong predictor of several pathologies including metabolic syndrome, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).
Traditional T2DM risk assessment
Traditional biomarker tests used to assess T2DM include FPG (Fasting Plasma Glucose), OGTT (Oral Glucose Tolerance Test), and HbA1c. However these cannot be considered a good assessment of risk as beta cell damage has already occurred, and insulin insensitivity is already underway.
It is widely recognized that people who are overweight are at higher risk of developing T2DM. However:
- Measuring waist circumference alone has limitations: studies have shown that waist circumference measures total abdominal fat reliably, but its association with visceral fat depends on visceral fat/ subcutaneous fat ratios that vary by gender and ethnicity.1
- Body mass index (BMI) (weight kg / height m2) is another common method of determining which patients are classed as overweight or obese, however it has limitations in measuring athletes and varies in reliability based on age, sex, and race.
As such adiponectin levels are a much more reliable indicator of at-risk patients!
A number of key publications have advocated the testing of adiponectin in clinical settings
- JAMA (2009): Adiponectin Levels and the Risk of Type 2 Diabetes – a Systematic Review and Meta-Analysis2
- A meta-analysis involving 13 prospective studies with a total of over 14,598 participants and 2,623 cases of type 2 diabetes
- Conclusion: higher adiponectin levels are associated with a lower risk of T2DM across diverse populations
- Preventative Cardiology (2015): Adiponectin, Type 2 Diabetes and Cardiovascular Risk3
- A prospective study following 5349 randomly selected men and women from the community, without T2DM or CV disease. Plasma adiponectin was measured at study entry. Median follow-up time was 8.5 years. During follow up, 136 participants developed T2DM. Following their diagnosis, 36 of the 136 participants experienced a CV event (myocardial infarction, ischaemic stroke, or CV death).
- Conclusions: increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.
Benefits of Randox Adiponectin
- A niche product from Randox allows us to offer specialized testing and the widest range of novel risk assessment reagents on the market
- Automated assay which removes the inconvenience and time-consumption associated with traditional ELISA-based testing
- Applications available for a wide range of biochemistry analyzers to ensure ease of programming and confidence in results
- Liquid ready-to-use reagents for convenience and ease-of-use
- Latex enhanced immunoturbidimetric method delivering high performance
- Extensive measuring range for measurement of clinically important results
- Complementary controls and calibrators available offering a complete testing package
Purchase the complete novel risk assessment package from Randox!
- Cystatin C
Contact firstname.lastname@example.org for a full quotation, citing ‘Randox novel risk assessment package’
Adiponectin Reagent, AO2999, R1 2 x 15.8 ml R2 2 x 8.4 ml
Adiponectin Reagent, AO2799, R1 4 x 65 ml R2 4 x 33.5 ml
Adiponectin Control Level 2, AO2801, 3 x 1 ml
Adiponectin Control Level 3, AO2802, 3 x 1 ml
Adiponectin Calibrator, AO2800, 4 x 1 ml
- Grundy, S. M., Neeland, I. J., Turer, A. and Vega, G. L.. Waist circumference as measure of abdominal fat compartments. Journal of Obesity, vol. 2013, 9 pages (2013).
- Li, S., Shin, H. J., Ding, E. L. and van Dam, R. M. Adiponectin Levels and Risk of Type 2 Diabetes. JAMA, vol. 302, no. 2, p. 179-188 (2009).
- Lindberg, S., Skov Jensen, J., Bjerre, Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppensen, J. and Mogelvang, R. Adiponectin, type 2 diabetes and cardiovascular risk. Preventative Cardiology, vol. 22, no. 3, p. 276-283 (2013).